Mainz Biomed NV (NASDAQ:QUCY – Get Free Report) was the recipient of a significant increase in short interest during the month of June. As of June 30th, there was short interest totaling 3,367,490 shares, an increase of 75.8% from the June 15th total of 1,915,904 shares. Approximately 23.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 8,070,542 shares, the days-to-cover ratio is currently 0.4 days.
Mainz Biomed Trading Up 3.4%
Shares of QUCY stock traded up $0.04 during trading hours on Friday, hitting $1.23. 722,669 shares of the company’s stock traded hands, compared to its average volume of 4,553,214. The firm has a 50 day moving average price of $1.98. The stock has a market cap of $18.03 million, a PE ratio of -0.03 and a beta of 2.28. Mainz Biomed has a 12 month low of $0.30 and a 12 month high of $4.93.
Analysts Set New Price Targets
A number of brokerages have recently commented on QUCY. Wall Street Zen upgraded Mainz Biomed to a “hold” rating in a research note on Saturday, June 6th. Weiss Ratings upgraded Mainz Biomed from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, May 11th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Mainz Biomed has a consensus rating of “Reduce”.
About Mainz Biomed
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Further Reading
- Five stocks we like better than Mainz Biomed
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
-american-depositary-shares-logo-1200x675.png){kind=logo}
